Precision Biosciences (DTIL)
NASDAQ:DTIL
Top Page
Precision BioSciences
(NASDAQ:DTIL)
Select Model
Select Model
Rating:52Neutral
Price Target:
$6.00
▲(3.09% Upside)
Action:ReiteratedDate:03/18/26
Overall score is held back primarily by weak financial performance (large losses, steep TTM revenue drop, and heavy cash burn). Technicals are constructive but overbought, while corporate updates and stated cash runway provide some support; valuation remains a headwind due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
Very low reported debt relative to equity provides lasting financial flexibility for an early‑stage biotech. This reduces interest burden and leaves capital structure room to fund R&D or negotiate partnerships without immediate leverage constraints, supporting multi‑year program execution.
Negative Factors
High cash burn
Persistent, large negative operating and free cash flow materially increases financing dependency. Over months this trend erodes runway if not offset by milestone receipts or financing, raising dilution risk and potentially forcing reprioritization or slowing of clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low reported debt relative to equity provides lasting financial flexibility for an early‑stage biotech. This reduces interest burden and leaves capital structure room to fund R&D or negotiate partnerships without immediate leverage constraints, supporting multi‑year program execution.
Read all positive factors
Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$143.91M
Dividend YieldN/A
Average Volume (3M)314.23K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-99.07%
EPS Growth-10347.56%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.05
Shares Outstanding24,726,694
10 Day Avg. Volume308,268
30 Day Avg. Volume314,229
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.05
Enterprise Value/Revenue-0.21
Enterprise Value/Gross Profit-0.23
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$36.33Price Target Upside524.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.53
Revenue Forecast (FY)$7.57M
Precision BioSciences Business Overview & Revenue Model
Company Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also p...
How the Company Makes Money
Precision BioSciences primarily generates revenue through collaboration and licensing arrangements tied to its ARCUS genome editing platform rather than through commercial product sales (as it is a clinical-stage company). Key revenue streams typi...
Precision BioSciences Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
67
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| Gross Profit | 31.51M | 68.70M | 48.73M | 25.10M | 115.53M |
| EBITDA | -49.40M | 13.53M | -32.04M | -62.79M | -20.27M |
| Net Income | -46.61M | 7.17M | -61.32M | -111.64M | -30.60M |
Balance Sheet | |||||
| Total Assets | 154.42M | 136.39M | 159.78M | 238.17M | 211.50M |
| Cash, Cash Equivalents and Short-Term Investments | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M |
| Total Debt | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M |
| Total Liabilities | 62.17M | 80.00M | 140.92M | 177.74M | 120.33M |
| Stockholders Equity | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M |
Cash Flow | |||||
| Free Cash Flow | -65.93M | -58.70M | -86.39M | -49.07M | -16.66M |
| Operating Cash Flow | -65.84M | -58.45M | -84.11M | -45.75M | -10.85M |
| Investing Cash Flow | -634.00K | -215.00K | 5.83M | -3.32M | -5.80M |
| Financing Cash Flow | 95.16M | 50.45M | 5.39M | 94.98M | 70.52M |
Precision BioSciences Technical Analysis
Positive
5.82
Price Trends
4.80
Positive
4.77
Positive
5.02
Positive
Market Momentum
0.31
Positive
54.06
Neutral
21.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Positive. The current price of 5.82 is below the 20-day moving average (MA) of 5.95, above the 50-day MA of 4.80, and above the 200-day MA of 5.02, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 54.06 is Neutral, neither overbought nor oversold. The STOCH value of 21.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DTIL.
Precision BioSciences Risk Analysis
Precision BioSciences disclosed 73 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precision BioSciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $143.91M | -1.14 | -96.96% | ― | -99.07% | -10347.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $58.89M | -1.19 | -53.71% | ― | ― | 21.17% | |
46 Neutral | $985.77M | -6.84 | -19.77% | ― | -10.26% | 144.62% | |
45 Neutral | $67.08M | -0.50 | -82.96% | ― | ― | 25.89% | |
41 Neutral | $55.59M | -0.74 | -33.05% | ― | -100.00% | 45.48% |
* Healthcare Sector Average
DTIL
Precision BioSciences
5.82
1.21
26.25%
CTMX
CytomX Therapeutics
4.56
4.10
902.20%
ACET
Adicet Bio
6.99
-3.23
-31.60%
IMA
ImageneBio
4.97
-8.59
-63.35%
ACRV
Acrivon Therapeutics, Inc.
1.52
0.01
0.66%
Precision BioSciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Highlights PBGENE-DMD Program and Trial
Positive
Mar 17, 2026
On March 17, 2026, Precision BioSciences hosted a live investor and key opinion leader webcast to provide an update on its PBGENE-DMD gene-editing program and the FUNCTION-DMD Phase 1/2 trial for Duchenne muscular dystrophy. Pediatric neurologist ...
Business Operations and StrategyFinancial Disclosures
Precision BioSciences Highlights 2026 Gene Editing Priorities
Positive
Jan 13, 2026
On January 12, 2026, Precision BioSciences outlined its 2026 strategic priorities centered on advancing its two lead ARCUS-based in vivo gene editing programs—PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy&...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.